

DAFTAR PUSTAKA

- Abotaleb, M. et al., 2018. Chemotherapeutic agents for the treatment of metastatic breast cancer: An update. *Biomedicine & Pharmacotherapy*, Volume 101, pp. 458-477.
- Admoun, C. & Mayrovitz, H. N., 2022. The Etiology of Breast Cancer. In: P. Harvey N. Mayrovitz, ed. *Breast Cancer*. Australia: Exon Publications, Brisbane, pp. 21-30.
- American Cancer Society, 2019. About Breast Cancer, Atlanta: cancer.org.
- Amir, E., Freedman, O. C., Seruga, B. & Evans, . D. G., 2010. Assessing
- American Medical Association, Volume 295, pp. 2742-2751.
- Anderson, C., Nichols, H. B., House, M. & Sandler, D. P., 2019. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer. *Cancer Prevention Research*, Volume 12, pp. 801-808.
- Antoniou, A. et al., 2014. Breast-Cancer Risk in Families with Mutations in PALB2. *NIH Public Access Author Manuscript*, 371(6), p. 497–506.
- Atalay, C., 2008. Are CA 15-3, CEA and CA 125 Predictors for Lymphatic and Vascular Spread In Breast Cancer?. *Erciyes Týp Dergisi (Erciyes Medical Journal)* , 30(4), pp. 218-224.
- Bafna, S., Kaur, . S. & Batra, S., 2010. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. *NIH Public Access Author Manuscript*, Volume 29, p. 2893–2904.
- Barak, V., Goike, H., Panaretakis, K. W., & Einarsson, R. (2020). Clinical utility of cytokeratins as tumor markers. *Clinical Biochemistry*, 83, 27–36. <https://doi.org/10.1016/j.clinbiochem.2020.05.004>
- Barke, L. D. & Freivogel, . M. E., 2017. Breast Cancer Risk Assessment Models and High-Risk Screening. *Radiol Clin N Am* , Volume 55, p. 457–474.
- Berg, W. A. et al., 2011. Breast Cancer: Comparative Effectiveness of Positron Emission Mammography and MR Imaging in Presurgical Planning for the Ipsilateral Breast. *radiology.rsna.org*, Volume 258, pp. 59-72.
- Brem, R. F., Lenihan, M. J., Lieberman, J. & Torrente, J., 2015. Screening Breast Ultrasound: Past, Present, and Future. *AJR*, Volume 204, p.

- Broët, P., de la Rochefordière, A., Scholl, S. M., Fourquet, A., Mosseri, V., Durand, J. C., Pouillart, P., & Asselain, B. (1996). Cancer controlatéral du sein: métastase ou second cancer primitif? [Contralateral breast cancer: metastasis or second primary cancer?]. *Bulletin du cancer*, 83(10), 870–876.
- C, K. et al., 2015. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update from the American Cancer Society. HHS Public Access-JAMA, 314(15), p. 1599–1614.
- Clarke, R. et al., 2003. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. *Oncogene*, Volume 22, p. 7316–7339.
- Collaborative Group on Hormonal Factors in Breast Cancer. (2022). Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118,964 women with breast cancer from 117 epidemiological studies. *The Lancet Oncology*, 13(11), 1141–1151. [https://doi.org/10.1016/S1470-2045\(12\)70425-4](https://doi.org/10.1016/S1470-2045(12)70425-4)
- Davies, A. A. et al., 2001. Role of BRCA2 in Control of the RAD51 Recombination and DNA Repair Protein. *Molecular Cell*, Volume 7, p. 273–282.
- de Bock, G. H., Vermeulen, K. M., Jansen, L., Oosterwijk, J. C., Siesling, S., Dorrius, M. D., Feenstra, T., Houssami, N., & Greuter, M. J. (2013). Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness. *British journal of cancer*, 108(8), 1579–1586. <https://doi.org/10.1038/bjc.2013.149>
- Duffy, M. J. (2022). Serum tumor markers in breast cancer: Are they of clinical value? *Clinical Chemistry*, 52(3), 345–351. <https://doi.org/10.1373/clinchem.2005.060343>
- Duffy, M. J. et al., 2004. High Preoperative CA 15-3 Concentrations Predict Adverse Outcome in Node-Negative and Node-Positive Breast Cancer: Study of 600 Patients with Histologically Confirmed Breast Cancer. *Clinical Chemistry*, 50(3), p. 559–563.
- Dumitrescu, R. G. & Cotarla, I., 2005. Understanding breast cancer risk - where do we stand in 2005?. *J. Cell. Mol. Med*, Volume 9, pp. 208–221.
- Evans, D. G., Howell, A., & Howell, S. J. (2020). Imaging features of breast cancer in BRCA1 and BRCA2 mutation carriers. *Clinical Radiology*, 75(4), 258–266. <https://doi.org/10.1016/j.crad.2019.12.006>

- Fellow, A. P. p. r. et al., 2012. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). *BJM*, pp. 1-15.
- Freitas, V. et al., 2022. Contralateral Breast Screening with Preoperative MRI: Long-term Outcomes for Newly Diagnosed Breast Cancer. *Radiology.rsna.org*, Volume 304, p. 297–307.
- Giger, M. L. et al., 2016. *American Roentgen Ray Society*, Volume 206, p.
- Greenwood, H. I., Heller, S. L., & Morris, E. A. (2024). Screening in women with BRCA mutations revisited. *Journal of Breast Imaging*, 6(1), 4–15. <https://doi.org/10.1093/jbi/wbad067>
- Guo, R., Yu, Y., Huang, Y., Lin, M., Liao, Y., Hu, Y., Li, Q., Peng, C., & Zhou, J. (2023). A nomogram model combining ultrasound-based radiomics features and clinicopathological factors to identify germline BRCA1/2 mutation in invasive breast cancer patients. *Heliyon*, 10(1), e23383. <https://doi.org/10.1016/j.heliyon.2023.e23383>
- andy, B., 2009. The Clinical Utility of Tumor Markers. *LABMEDICINE*, Volume 40, pp. 99-103.
- Healey, E. A., Cook, E. F., Orav, E. J., Schnitt, S. J., Connolly, J. L., & Harris, J. R. (1993). Contralateral breast cancer: clinical characteristics and impact on prognosis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 11(8), 1545–1552. <https://doi.org/10.1200/JCO.1993.11.8.1545>
- Hooley, R. J., Scoutt, L. M. & Philpotts, L. E., 2013. Breast Ultrasonography: State of the Art1. *radiology.rsna.org*, Volume 268, p. 3.
- <https://sugarytooth.wordpress.com/tag/mri/>, 21 Agust.
- Jayne, C. & Iliadis, L., 2011. *Engineering Applications of Neural Networks*. A. Joe Turner, Seneca, SC, USA ed. New York: IFIP Advances in Information and Communication Technology.
- Jeon, J., Kim, S. H., & Park, J. (2024). Effectiveness of alternating mammography and MRI for breast cancer screening in high-risk women. *Cancer*, 130(2), 259–269. <https://doi.org/10.1002/cncr.25971>
- Jordan, V. C., 2007. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. *NIH Public Access Author Manuscript*, Volume 72, p. 829–842.
- Journal of Oncological Sciences*, pp. 1-7.

- Kabel, A. M., 2017. Tumor markers of breast cancer: New perspectives.
- Kementerian Kesehatan RI, 2013. Riset Kesehatan Dasar. Dalam: Riset Kesehatan Dasar. Jakarta: Kementrian Kesehatan RI, pp. 1-471.
- Kim, H. J., Park, J., Lee, S. H., & Cho, N. (2022). Association between BRCA mutation status, ultrasound BI-RADS category, and serum tumor markers in breast cancer. *Breast Cancer Research and Treatment*, 196(2), 245–255. <https://doi.org/10.1007/s10549-021-06466-8>
- Kim, J. H., Kim, S. Y., & Lee, S. H. (2020). Age at menarche and mammographic density: Analysis in Korean women. *Breast Cancer Research and Treatment*, 181(1), 209–217. <https://doi.org/10.1007/s10549-020-05608-y>
- Kim, S. Y., Cho, N., Yi, A., Koo, H. R., Park, J. S., & Moon, W. K. (2020). Sonographic characteristics of breast cancers in BRCA1 and BRCA2 mutation carriers: Comparison with non-carriers. *Ultrasound in Medicine & Biology*, 46(8), 1994–2004. <https://doi.org/10.1016/j.ultrasmedbio.2020.04.005>
- Kollias, J., Ellis, I. O., Elston, C. W., & Blamey, R. W. (1999). Clinical and histological predictors of contralateral breast cancer. *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*, 25(6), 584–589. <https://doi.org/10.1053/ejso.1999.0711>
- Kwong A, Ho CYS, Shin VY, Au CH, Chan TL, Ma ESK (2022). How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer? *BMC Medical Genomics*. 2022;15:122. <https://doi.org/10.1186/s12920-022-01270-4>
- LAESSIG, D. et al., 2007. Importance of CEA and CA 15-3 during Disease Progression in Metastatic Breast Cancer Patients. *ANTICANCER RESEARCH* , Volume 27, pp. 1963-1968.
- Lagendijk, M. et al., 2018. Breast conserving therapy and mastectomy revisited: Breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. *International Journal of Cancer (IJC)*, Volume 142, p. 165–175.
- Lee, J., Jung, J. H., Kim, W. W., Park, C. S., Lee, R. K., Kim, H. J., Kim, W. H., & Park, H. Y. (2020). Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma. *BMC cancer*, 20(1), 934. <https://doi.org/10.1186/s12885-020-07443-7>

- Lee, Y., Park, H. S., Kim, J., & Cho, N. (2022). Association between breast density and tumor marker CA 15-3 in BRCA mutation carriers. *Clinical Breast Cancer*, 22(5), e520–e527. <https://doi.org/10.1016/j.clbc.2022.02.005>
- Lehman, C. D., Gatsonis, C., Kuhl, C. K., Hendrick, R. E., Pisano, E. D., Hanna, L., ... & Schnall, M. D. (2007). MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. *New England Journal of Medicine*, 356(13), 1295-1303.
- Li, C., Wang, Y., Li, Y., Zhang, Q., & Zhang, Y. (2022). Hormonal contraceptive use and breast density: Evidence from Asian women. *BMC Women's Health*, 22, 121. <https://doi.org/10.1186/s12905-022-01690-8>
- Li, J., Huang, Y., Zhou, Y., & Sun, L. (2023). Menopausal status and breast density in breast cancer patients: A sonographic perspective. *European Journal of Radiology*, 162, 110775. <https://doi.org/10.1016/j.ejrad.2023.110775>
- Li, L. et al., 2016. Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI): A retrospective comparison in 66 breast lesions. *Diagnostic and Interventional Imaging-ELSEVIER*, Volume 854, p. 11.
- Li, L., Zhou, Y., Wang, X., & Sun, L. (2022). Differences in ultrasound and mammographic features between BRCA1- and BRCA2-associated breast cancers in a Chinese cohort. *BMC Cancer*, 22, 745. <https://doi.org/10.1186/s12885-022-09890-7>
- Li, W., Liu, Q., Deng, X., Chen, Y., Liu, S., Story, M., & Luo, J. (2020). Association between obesity and puberty timing: A systematic review and meta-analysis. *International Journal of Environmental Research and Public Health*, 14(11), 1266. <https://doi.org/10.3390/ijerph14111266>
- Lian, W., Zhang, Y., Han, S., & Zhang, Y. (2021). Serum CA 15-3 levels and imaging features in BRCA1/2 mutation carriers and non-carriers with breast cancer. *BMC Cancer*, 21, 1187. <https://doi.org/10.1186/s12885-021-08900-3>
- Mainiero, M. B. et al., 2023. ACR Appropriateness Criteria Breast Cancer Screening. *The American College of Radiology*, Volume 14, pp. 1546- 1440.
- Mandrekar, J. N. (2020). Receiver operating characteristic curve in diagnostic test assessment. *Journal of Thoracic Oncology*, 5(9), 1315–1316. <https://doi.org/10.1097/JTO.0b013e3181ec173d>

- Manuaba, T. . W., 2010. Panduan Penatalaksanaan Kanker Solid Peraboi 2010. Jakarta: Sagung Seto.
- Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., & Antoniou, A. C. (2021). Cancer histopathology and imaging characteristics in BRCA1 and BRCA2 mutation carriers. *JAMA Oncology*, 7(6), 882–891. <https://doi.org/10.1001/jamaoncol.2021.0310>
- Mavaddat, N., Peock, S., Frost, D., et al. (2020). Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. *Journal of the National Cancer Institute*, 105(11), 812–822. <https://doi.org/10.1093/jnci/djt095>
- Mehrgou, A. & Akouchekian, M., 2016. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. *Medical Journal of the Islamic Republic of Iran (MJIRI)*, Volume 30, p. 369.
- Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., Sun, P., Foulkes, W. D., & Narod, S. A. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 22(12), 2328–2335. <https://doi.org/10.1200/JCO.2004.04.033>
- Miglioretti, D. L., Gard, C. C., Carney, P. A., Onega, T., Buist, D. S., Sickles, E. A., ... & Kerlikowske, K. (2020). When radiologists perform best: The learning curve in screening mammogram interpretation. *Radiology*, 273(1), 45–52. <https://doi.org/10.1148/radiol.14140511>
- Models. Published by Oxford University Press *JNCI*, 102(10), p. 680.
- Monticciolo, D. L. et al., 2017. Breast Cancer Screening for Average-Risk Women: Recommendations From the ACR Commission on Breast Imaging. *American College of Radiology*, pp. 1546-1440.
- Murakami, W., Tozaki, M., Nakamura, S., Ide, Y., Inuzuka, M., Hirota, Y., Murakami, K., Takahama, N., Ohgiya, Y., & Gokan, T. (2019). The clinical impact of MRI screening for BRCA mutation carriers: the first report in Japan. *Breast cancer (Tokyo, Japan)*, 26(5), 552–561. <https://doi.org/10.1007/s12282-019-00955-6>
- Nandi, M. et al., 2014. Hypofractionated Radiotherapy for Breast Cancers - Preliminary Results from a Tertiary Care centre in eastern India. *Asian Pacific Journal of cancer prevention* , Volume 15, pp. 2505-2510.
- Nyante, S. J., Sherman, M. E., Pfeiffer, R. M., & Berrington de González, A. (2020). Mammographic density and breast cancer risk in mutation

- carriers. *Breast Cancer Research*, 22, 106.
<https://doi.org/10.1186/s13058-020-01351-4>
- O'Connor, M., Brandt, K. R., Vachon, C. M., & Hieken, T. J. (2021). Effect of combined hormonal contraceptives on mammographic breast density: A longitudinal study. *Breast Cancer Research*, 23, 75.
<https://doi.org/10.1186/s13058-021-01452-5>
- Panchal, H. & Matros, E., 2017. Current Trends in Post-Mastectomy Breast Reconstruction. *HHS Public Access Author manuscript*, Volume 140, p. 7S–13S.
- Partain, N. et al., 2018. Mammographic density changes in surgical weight loss-an indication for personalized screening. *BMC Medical Imaging*, p. 18:10 .
- Patel, H. K. & Bihani, T., 2017. Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer. *s.l., Pharmacology and Therapeutics*.
- Peairs, K. S., Choi, Y., Stewart, R. W. & Sateia, H. F., 2017. Screening for breast cancer. *Seminars in Oncology*, 004 02, pp. 1-32.pp. 1-10.
- Rajaf, B., 2012. Imaging of the Breast-Technical Aspects and Clinical Implication. Teodora Smiljanic ed. Croatia: Janeza Trdine.
- Richardson, H., Johnston, D., Pater, J. & Goss, P., 2007. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. *CURRENT ONCOLOGY*, Volume 14, pp. 89-95.
- RISSAN, T. J., MAKKARAIN, H. P., Sakkinen, M. A. A. & LINDHOLM, E. L., 2015. MAMMOGRAPHY AND ULTRASOUND IN THE DIAGNOSIS OF CONTRALATERAL BREAST CANCER. *ACTA RADIOLOGICA* 1995,
- Rosel, J. et al., 2017. Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen. *ACTA ONCOLOGICA*, Volume 56, p. 614–617.
- Saad, A. & Abraham, J., 2008. Role of Tumor Markers and Circulating Tumors Cells in the Management of Breast Cancer. *Home Of The Jurnal ONCOLOGY*, 22(7).
- Sacher & A, R., 2004. Tinjauan klinis hasil pemeriksaan laboratorium, Ed. 11.
- Schneble, E. J. et al., 2014. Current Approaches and Challenges in Early Detection of Breast Cancer Recurrence. *Ivyspring International Publisher*, Volume 5(4), pp. 281-290.

- Seo, B. K., Kim, S., & Lee, J. (2022). Lactation history and breast tissue composition assessed by ultrasound tomography. *Journal of Ultrasound in Medicine*, 41(8), 2121–2130. <https://doi.org/10.1002/jum.15955>
- Shen, Q. et al., 2008. MUC1 Initiates Src-CrkL-Rac1/Cdc42–Mediated Actin Cytoskeletal Protrusive Motility after Ligating Intercellular Adhesion Molecule-1. *Mol Cancer Res*, 6(4), pp. 555-567.
- Sobri, B. F., Azhar, Y., Wibisana, I. G. & Rachman, A., 2017. *Manajemen Terkini Kanker Payudara*. Jakarta: Media Aesculapius.
- Suega, K. & Bakta,, . I. M., 2006. *Buku ajar ilmu Penyakit Dalam : Penanda tumor dan aplikasi klinik. (ket. lihat bab. 197) (halaman 830-837). IV ed.* Jakarta: FKUI.
- sugarytooth.wordpress.com, 2017. *Simply Radiology*.
- Sung, H. et al., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA CANCER J CLIN*, Volume 71, p. 209–249.
- Sung, H., Yang, H. H., & Cho, N. (2021). Age-related changes in breast tissue composition on ultrasonography and their clinical implications. *Ultrasound in Medicine & Biology*, 47(9), 2486–2495. <https://doi.org/10.1016/j.ultrasmedbio.2021.05.012>
- Sung, J. S., Li, J., Lee, C. H., & Morris, E. A. (2021). Breast density patterns in BRCA mutation carriers: Implications for screening. *American Journal of Roentgenology*, 216(3), 735–744. <https://doi.org/10.2214/AJR.20.23560>
- Suyatno, et al., 2023. *Panduan Tatalaksana Kanker Payudara. Perhimpunan Ahli Bedah Onkologi Indonesia (PERABOI): Perhimpunan Ahli Bedah Onkologi Indonesia (PERABOI)*.
- Taneja, S., Jena, A., Zaidi, S. M., & Khurana, A. (2012). MRI evaluation of the contralateral breast in patients with recently diagnosed breast cancer. *The Indian journal of radiology & imaging*, 22(1), 69–73. <https://doi.org/10.4103/0971-3026.95408>
- Theriault, R. L. & et, al, 2013. Breast Cancer, Version 3.2013: Featured Updates to the NCCN Guidelines. *NIH Public Access Author Manuscript*, Volume 11(7), p. 753–761.
- Venta,, L. A., Dudiak, C. M., Salomon, C. G. & Flisak, M. E., 1994. *Sonographic Evaluation of the breast. Scientific Exhibit , Volume 14*, pp. 29-50.

- Visvanathan, K. et al., 2009. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. American Society of Clinical Oncology, Volume 27, pp. 3235-3258.
- Wan, D., 2013. Buku Ajar Onkologi Klinis Edisi 2. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia.
- Wang, Q., Zhang, X., & Yu, Y. (2021). Reproductive history and sonographic breast density among Chinese women. BMC Women's Health, 21, 189. <https://doi.org/10.1186/s12905-021-01334-4>
- Wang, Q., Zhang, X., & Yu, Y. (2022). Reproductive history and mammographic breast density among Chinese women with breast cancer. BMC Women's Health, 22, 189. <https://doi.org/10.1186/s12905-022-01734-z>
- Wang Z, Zhang J, Zhang Y, Deng Q, Liang H (2018). *Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses*. International Journal of Molecular Medicine. 2018;42:3542–3550. <https://doi.org/10.3892/ijmm.2018.3870>
- Winer, E. P. et al., American Society of Clinical Oncology. American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With. American Society of Clinical Oncology, Volume 23, pp. 619-629.
- Women at High Risk of Breast Cancer: A Review of Risk Assessment
- World Health Organization, 2011. Manual of diagnostic ultrasound. s.l.:World Federation for Ultrasound in Medicine and Biology.
- www.cureus.com, 2023. Adenomyoepithelioma of the Breast in the Setting of Prior Contralateral Breast Malignancy. <https://www.cureus.com/articles/148767-adenomyoepithelioma-of-the-breast-in-the-setting-of-prior-contralateral-breast-malignancy#!/>, 18
- www.diagnosticimaging.com, 2023. What a New MRI Study Reveals About Enhancing Parenchyma in Women with Extremely Dense Breasts. <https://www.diagnosticimaging.com/view/mri-study-enhancing-parenchyma-women-with-extremely-dense-breasts>, 10 Agust.
- Yang, X., Li, X., Sun, L., & Tang, J. (2020). Ultrasonographic breast density and its association with age and reproductive factors in Chinese women. European Journal of Radiology, 127, 108992. <https://doi.org/10.1016/j.ejrad.2020.108992>

- Yasin, R. & Ghany, E. . A. E., 2019. BIRADS 4 breast lesions: comparison of contrast-enhanced spectral mammography and contrast-enhanced MRI. *Egyptian Journal of Radiology and Nuclear Medicine*, Volume 34,
- Yoon, T. I., Kwak, B. S., Yi, O. V., Kim, S., Um, E., Yun, K. W., Shin, H. N., Lee, S., Sohn, G., Chung, I. Y., Kim, J., Ko, B. S., Lee, J. W., Son, B. H., Ahn, S. H., & Kim, H. J. (2019). Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. *Breast cancer research and treatment*, 173(3), 657–665. <https://doi.org/10.1007/s10549-018-5031-4>
- Zeng, Y., Li, X., Chen, Y., & Wang, J. (2023). Correlation of CA 15-3 and imaging characteristics in BRCA-associated breast cancer: A retrospective cohort study. *Frontiers in Oncology*, 13, 1156239. <https://doi.org/10.3389/fonc.2023.1156239>